
NDRA Stock Forecast & Price Target
NDRA Analyst Ratings
Bulls say
ENDRA Life Sciences Inc is poised for growth due to its innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which could significantly improve the diagnosis and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in over one billion individuals globally. The anticipated FDA approval within the next year is expected to boost investor sentiment and enhance stock value, reflecting a robust net present value (NPV) analysis that suggests considerable potential upside. Furthermore, TAEUS promises cost-effective and precise capabilities compared to current diagnostic tools, which could capture a substantial market share within the healthcare sector.
Bears say
ENDRA Life Sciences Inc. reported a net loss of $1.6 million, equating to an earnings per share (EPS) of $(2.10), which exceeded previous estimates of $(1.95). The company also experienced another loss of $1.2 million, with an EPS of $(1.71), aligning with prior estimates but indicating persistent financial challenges. Furthermore, significant risks impacting the stock's outlook include liquidity concerns, potential failures in clinical efficacy and regulatory approval, difficulties in commercialization, and the pressing competition within the biotech and medtech sectors.
This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
NDRA Analyst Forecast & Price Prediction
Start investing in NDRA
Order type
Buy in
Order amount
Est. shares
0 shares